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Abstract
Purpose—Diabetes has been associated with increased risk of breast cancer in a number of
epidemiologic studies, but its effects on survival among women diagnosed with breast cancer have
been examined less frequently. Importantly, prior investigations have rarely considered the
influence of factors associated with diabetes such as obesity, age at diabetes diagnosis, duration of
diabetes, or diabetes treatments.
Methods—We evaluated the effect of self-reported diabetes on breast cancer incidence and
mortality in the Long Island Breast Cancer Study Project, which includes 1,447 breast cancer
cases and 1,453 controls. Follow-up data for all-cause (n = 395) and 5-year breast cancer-specific
mortality (n = 104) through December 2005 were determined for case women from the National
Death Index. Adjusted logistic regression and Cox proportional hazards models were used to
estimate odds ratios (OR) and hazards ratios (HR), respectively.
Results—Postmenopausal women with diabetes were at increased risk of developing breast
cancer [OR = 1.35; 95 % confidence interval (CI) = 0.99–1.85], as were those who were not of
white race regardless of menopausal status [OR = 3.89; 95 % CI = 1.66–9.11]. Among case
women, diabetes was associated with a modestly increased risk of death from all causes [HR =
1.65; 95 % CI = 1.18–2.29], an association that was stronger in women who were obese at breast
cancer diagnosis [HR = 2.49; 94 % CI = 1.58–3.93]. In analyses restricted to diabetics, there was
no statistically significant effect of duration of diabetes or type of treatment on breast cancer
incidence or mortality.
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Conclusions—Our findings suggest that diabetes may increase incidence of breast cancer in
older women and non-whites, and mortality due to all causes.
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Introduction
Diabetes and breast cancer are increasing health concerns for women worldwide,
particularly in older women [1]. Approximately 90–95 % of all cases of diabetes diagnosed
are classified at type 2 diabetes (T2D), and it is currently estimated that over 10 % of
women in the United States over the age of 20 have T2D, including those with undiagnosed
disease [2]. T2D is characterized by insulin resistance and hyperinsulinemia, is associated
with high BMI that is a well-established risk factor for breast cancer in postmenopausal
women [3], and is associated with poor prognosis regardless of menopausal status [4, 5]. It
is thought that T2D affects risk of developing breast cancer through the direct effects of
insulin on breast tissue, or indirectly through the increase in sex steroids due to the
inhibition of sex hormone-binding globulin (SHBG), increased insulin-like growth factor-I
(IGF-I) production, and disruption of adipokines [6, 7]. These changes in circulating
hormone levels can lead to abnormalities in cellular growth and regulation [8].
T2D has primarily been shown to increase the risk of breast cancer incidence, with a recent
large meta-analysis reporting about a 20 % increase in risk for both case–control and cohort
studies [9]. However, few population-based studies of survival after a breast cancer
diagnosis have reported on this potentially important pathway [10–12] and even fewer have
reported breast cancer-specific mortality [11, 13]. The biologic plausibility of an association
with mortality is strong, as many components of diabetes have been linked to breast cancer
incidence and prognosis including centralized obesity, insulin resistance, and raised fasting
plasma glucose [6]. Furthermore, hyperinsulinemia has been associated with risk of
recurrence and mortality in breast cancer [14].
For women with diabetes, the risk of developing or dying from breast cancer may also be
affected by variations in the management of their diabetes, including types and length of
treatments. There is encouraging evidence that metformin, an insulin sensitizer and the most
commonly used therapy for patients with T2D, may decrease breast cancer risk by reducing
hepatic glucose output [15]. Other treatments, however, such as insulin, or secretogogues,
that stimulate insulin production, may increase cancer risk and death [16, 17]. There have
been few studies that have investigated diabetes treatment on breast cancer risk [18, 19], and
we are not aware of any studies that have investigated the influence of diabetes treatment in
terms of survival.
Because diabetes is increasingly becoming a worldwide health problem where the number of
women at risk is growing, it is important to understand the impact of diabetes and diabetes
treatments on risk of developing breast cancer and survival after a breast cancer diagnosis.
To investigate the effects of diabetes and diabetes treatments on risk of breast cancer and
mortality, we conducted a large population-based study.
Materials and methods
This study draws upon data that were collected from participants as part of the Long Island
Breast Cancer Study Project (LIBCSP), a population-based study of English-speaking
residents of Nassau and Suffolk counties of Long Island, NY [20]. The study reported here
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utilizes resources from both the case–control and the follow-up studies of the LIBCSP, as
described below.
Study population
Case–control study—Eligible case participants were women newly diagnosed with a
first, primary in situ or invasive breast cancer between August 1, 1996 and July 31, 1997.
Cases were identified using a rapid reporting system established specifically for the LIBCSP
and were confirmed by physicians’ and medical records. The attending physician was
contacted to confirm study eligibility and to seek permission to contact the patient. Controls
were women who were residents of the same two counties, frequency matched by 5-year age
group to the expected age distribution of cases. Potentially eligible control women were
identified by Waksberg’s method of random digit dialing (RDD) [21] for those under 65
years of age, and by Health Care Finance Administration (HCFA) rosters for those 65 years
of age and older. Institutional review board (IRB) approval of the study protocol was
obtained from each collaborating institution and participating hospital, and written informed
consent was obtained from each participant prior to the baseline interview. A total of 1,508
women with breast cancer, of which 1,273 had invasive breast cancer, and 1,556 control
women participated in the baseline case–control study interview. In the LIBCSP population,
93 % or participants reported their race as white, 4.8 % as black, and 2.2 % as other, which
is consistent with the U.S. Census data for these two NY counties [20].
Follow-up study—The population-based cohort of women with breast cancer who
participated in the baseline interview (n = 1,508) have been followed to determine complete
first course of treatment for the first primary breast cancer diagnosis and vital status.
Data collection
Baseline, case–control data—Diabetes and most of the covariate data used in this
analysis were collected as part of the LIBCSP baseline case–control interview, which for
case women occurred about 2 months after the initial breast cancer diagnosis. The baseline
structured questionnaire was administered in-home by a trained interviewer and took
approximately 2 h to complete. Information obtained from the baseline questionnaire
includes reproductive and menstrual history, exogenous hormone use (hormone replacement
or oral contraceptives), family history of cancer, physical activity, smoking history, alcohol
intake, demographic characteristics, and diabetes status. Descriptive characteristics for the
entire LIBCSP study have been previously published [20]. As part of the baseline interview,
a modified Block food frequency questionnaire was self-completed by 98 % of all LIBCSP
respondents; these data were used to estimate intake of total fat and calories in the year prior
to the baseline interview.
Additionally, as part of the baseline case–control study, medical records of the cases were
abstracted for tumor stage, estrogen receptor (ER) status, progesterone receptor (PR) status,
and initial course of treatment. Nearly two-thirds of the baseline interviews with cases
occurred prior to the initiation of chemotherapy.
Diabetes status—Diabetes status was determined at the baseline, case–control interview.
Participants were asked whether they had ever been told by a physician that they had
diabetes, sugar diabetes, or high blood sugar. There were 7 participants (3 cases, 4 controls)
with missing information on diabetes status. No distinction was indicated as to diabetes type,
however, based on prior literature, in order to increase the probability that our population
was limited to those with type 2 diabetes, women diagnosed with diabetes before the age of
30 were excluded from the analyses (n = 19) [22, 23], resulting in a total of 1,495 cases and
1,543 controls available for analysis. If the participant had reported having diabetes, they
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were asked when they were diagnosed and were asked about medication use. Medication use
was determined from the questionnaire where women responded to a question asking
whether they had taken medication for diabetes for 3 or more consecutive months. Women
reported the names of the medications used, and the duration they used each medication.
Reports of using insulin, hepatic glucose production inhibitors (metformin), and/or an
insulin secretogogue (majority of which were sulfonylureas, some were meglitinides) were
classified as having used a medication.
Follow-up data among women with breast cancer—For women with breast cancer
who participated in the LIBCSP baseline interview, follow-up telephone interviews were
conducted in 2002–2004 by trained interviewers using a structured questionnaire with 1,098
case participants (of which 8 % were completed with a proxy). The follow-up interview
included ascertainment of information on completed course of treatment for the first primary
breast cancer diagnosis. These self-reported treatment data were compared with updated
information from the medical records, which were retrieved as part of the follow-up and
abstracted for 598 breast cancer cases. Trained abstractors reviewed medical records to
determine the complete course of treatment for the first primary breast cancer diagnosis, and
these data were compared with the respondent’s self-reported treatment from the follow-up
interview. A very high concordance was found between information abstracted from
medical records and self-reported radiation therapy (Kappa = 0.97), chemotherapy, (Kappa
= 0.96), and hormone therapy (Kappa = 0.92). Thus, self-reported breast cancer treatment
was used for this analysis. At the time of the follow-up medical record review, nodal status
for each woman’s first primary breast cancer diagnosis was also ascertained.
Study outcome for the follow-up analyses—For the LIBCSP follow-up, the National
Death Index (NDI) was used to ascertain all-cause and breast cancer-specific mortality
among case participants. Cases were followed from diagnosis until December 31, 2005 for a
mean of 96.4 months (range, 2.7–113.0). Among the 1,495 women in this study diagnosed
with breast cancer, 303 (20.3 %) deaths occurred. Based on International Classification of
Diseases (ICD) codes 174.9 and C-50.9 listed as a primary or secondary code on the death
certificate, 106 (35.0 %) deaths after 5 years of follow-up were due to breast cancer.
Statistical methods
Risk of developing breast cancer and demographic factors were compared between
participants with a self-reported diabetes diagnosis and those without a diabetes diagnosis
using t tests and chi-square tests. All tests of statistical significance are two-sided and
considered significant at the 0.05 level. All analyses were carried out using the statistical
software package SAS version 9.2 (SAS Institute Inc., Cary, NC).
Case–control analyses—For the assessment of the association between the risk of
developing breast cancer and a history of diabetes, odds ratios (ORs) and 95 % confidence
intervals (CI) were calculated using unconditional logistic regression models [24]. All
models were adjusted for 5-year age group at diagnosis. Additional factors considered as
potential confounders included: variables related to demographic factors (race, income,
education, marital status, religion), reproduction (parity, age at first live birth, breast
feeding), and menstruation (age at menarche, menopausal status). Exogenous hormone use
was also considered (hormonal birth control, hormone replacement among postmenopausal
women) as was medical history (benign breast disease, family history of breast cancer), and
lifestyle factors (alcohol consumption, dietary fat and total caloric intake, cigarette smoking,
physical activity, and body size measured as body mass index [BMI; weight in kilograms
divided by height in meters squared]). Using manual backward elimination, potential
confounders were removed from models. Variables remained in the final models if their
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exclusion changed the estimate of effect by ≥10 % [24]. Adjustment for most covariates did
not alter the estimates of effect by more than 10 %, and therefore associations reported are
only adjusted for 5-year age group, menopausal status (pre- vs. postmenopause), race
(whites vs. blacks and others), and body size (BMI<30 vs. BMI ≥30). All case–control
analyses were carried out on a dataset restricted to participants without missing values for
menopausal status, race, or obesity resulting in a final dataset of 1,447 cases and 1,453
controls.
We also evaluated the effects of age at diabetes diagnosis, duration of diabetes, and diabetes
medication use among those who reported having been diagnosed with diabetes. ORs and 95
% CI were calculated for the association between breast cancer and age at diabetes diagnosis
(±55 years), median duration of diabetes (±7 years), whether they had ever received
medication for diabetes for 3 or more consecutive months, and type of medication (insulin,
metformin, secretogogues). Age at diabetes diagnosis and duration of diabetes were
mutually adjusted for each other. Additionally, all types of diabetes medications we
evaluated in the same model.
Effect measure modification on the multiplicative scale between categorical covariates was
examined comparing the log likelihood statistic for logistic regression models with and
without the cross-product terms [25]. We evaluated models stratified by age at breast cancer
diagnosis (±65 years), menopausal status (pre- and postmenopause), BMI one year prior to
breast cancer diagnosis (<25, ≥25–<30, ≥30), lifetime average physical activity (ever,
never), lifetime average alcohol consumption (ever, never), median average daily caloric
intake (±1,251.1 kcal/day), hormone replacement (ever, never), and race (white, black,
other).
Survival analysis—Cox proportional hazards regression [25] was used to estimate hazard
ratios (HR) and 95 % confidence intervals (CI) for all-cause and breast cancer-specific
mortality in relation to a diabetes diagnosis reported at the time of baseline interview. Since
most women who die as a result of their breast cancer diagnosis usually do so within 5
years, we presented only 5-year survival for breast cancer-specific deaths. Models re-run
with follow-up time through 2005 were nearly identical to those limited to 5 years.
To investigate the differences in associations between diabetes and survival, analyses were
stratified by selected covariates: age at breast cancer diagnosis (±65 years), menopausal
status (pre- and postmenopause), BMI one year prior to breast cancer diagnosis (<25, ≥25–
<30, ≥30), lifetime average physical activity (ever, never), lifetime average alcohol
consumption (ever, never), median average daily caloric intake (±1,251.1 kcal/day),
hormone replacement (ever, never), and race (white, black, other). Associations were also
evaluated by stratification on the tumor characteristics, ER status (negative, positive), PR
status (negative, positive), tumor stage (in situ, invasive), nodal status (node negative, node
positive), and tumor size (<2 cm, ≥2 cm).
All models were adjusted for age at diagnosis. In addition to consideration of the covariates
listed above for the case–control analyses, for the survival analyses, we also considered as
potential confounders other factors including history of co-morbidities reported at the
baseline interview (high cholesterol, history of blood clots, hypertension, previous
myocardial infarction [MI], and stroke), tumor characteristics (tumor stage, tumor size, and
nodal status), and treatment undergone for the original breast cancer diagnosis. Adjustment
for most covariates did not alter the estimates of effect by more than 10 %, and therefore
associations reported are adjusted for 5-year age group, menopausal status, race, body size,
and MI only. All survival analyses were carried out on a dataset restricted to participants
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with complete data for menopausal status, race, obesity, and MI resulting in a final dataset
of 1,444 breast cancer cases.
Results
In Table 1, we report the distribution of characteristics of the LIBCSP stratified by self-
reported diabetes from questionnaire data recorded in 1996–1997. There were 219 (7.2 %)
participants in our population who reported having a diabetes diagnosis. Compared to non-
diabetics, those with diabetes tended to be postmenopausal at diagnosis, have a higher BMI
at diagnosis, and were less likely to engage in physical activity, drink alcohol or take
hormone replacement than women without diabetes. Mean follow-up for women with breast
cancer was 86.8 months for those with diabetes and 97.4 months for non-diabetics. There
were no differences between those with and without diabetes according to tumor
characteristics (ER/PR positivity, nodal status) or treatment type.
Case–control analysis
After adjustment for obesity, menopausal status, and race, the odds ratio for the association
between diabetes and risk of developing breast cancer was slightly elevated, although not
statistically significant (OR = 1.27; 95 % CI = 0.95–1.69) (Table 2). Estimates did not
change appreciably with additional adjustment for other potential confounders such as
physical activity, age at menarche, alcohol consumption, daily caloric intake, hormonal birth
control, hormone replacement, education, or income (data not shown). We found a modest
association of diabetes on the risk developing breast cancer among postmenopausal women,
which was of borderline significance (OR = 1.35; 95 % CI = 0.99–1.85). The diabetes–
breast cancer association was most pronounced when we limited the analysis to women over
the age of 65 at breast cancer diagnosis (OR = 1.59; 95 % CI = 1.04–2.44).
When evaluating the potential effect measure modification of lifestyle factors on the
association between diabetes and breast cancer, we found no association between those who
were obese at diagnosis (OR = 0.99; 95 % CI = 0.65–1.53), whereas those who were not
obese had an increased association (OR = 1.52; 95 % CI = 1.03–2.25). The diabetes–breast
cancer associations were strengthened with decreasing BMI and were over twofold for those
with a BMI between 18.5 and 25 at diagnosis (OR = 2.13; 95 % CI = 1.10–4.13) (data not in
table). Similarly, we saw stronger associations for those who gained less than 30 lbs since
age 20 (OR = 1.72; 95 % CI = 0.92–3.20) and had either lost weight or gained less than 13.5
lbs after the age 50 (OR = 1.65; 95 % CI = 1.00–2.74; OR = 1.50; 95 % CI = 0.74–3.04,
respectively; data not in table). We also observed increased associations among those who
consumed fewer daily calories (OR = 1.66; 95 % CI = 1.10–2.52). Among women who did
not engage in regular lifetime physical activity (OR = 1.60; 95 % CI = 0.99–2.59), we found
that women with diabetes had increased risk of developing breast cancer, an association that
approached statistical significance. We found no evidence of effect modification of the
association between diabetes and breast cancer for use of postmenopausal hormones.
We observed modification of the effect of diabetes on breast cancer for race. After
additional adjustment for both income and education, white women had no increased risk of
developing breast cancer with diabetes; however, those of races other than white had over a
threefold increase in the OR (OR = 3.89; 95 % CI = 1.66–9.11), but the estimate was
unstable as reflected by the wide confidence intervals.
Survival analysis
Through 2005, there were 295 deaths overall and 148 deaths due to breast cancer, 104 of
which occurred within 5 years of diagnosis. After adjusting for age, menopausal status, race,
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obesity, and history of MI, women who reported having a diabetes diagnosis had increased
all-cause mortality compared to women who did not have diabetes (HR = 1.65; 95 % CI =
1.18–2.29) (Table 3). This association was stronger among postmenopausal women.
Additionally, women who were older age at diagnosis (≥65 years) also had higher mortality
than those who were younger.
When stratified by body size, we found a higher risk of all-cause mortality in association
with diabetes among those with a BMI of 30 or greater (HR = 2.49; 95 % CI = 1.58–3.93)
than that seen in those with a BMI of less than 30 (HR = 1.20; 95 % CI = 0.73–1.99).
Additionally, among women who were ever regular drinkers, although the association was
not statistically significant, we found a stronger association for diabetes on breast cancer-
specific mortality (HR = 2.14; 95 % CI = 0.90–4.69), whereas there was no increased risk of
breast cancer death in association with diabetes among never drinkers.
Disease duration and medication use
Among diabetics, there was no consistent association between age at diabetes diagnosis,
years since diabetes diagnosis, or diabetes medication use on the risk of developing breast
cancer or mortality among cases (Table 4). After adjustment for duration of diabetes, modest
non-significant increases in risk of developing breast cancer and all-cause mortality and
diabetes were observed for women who were diagnosed with diabetes age after the age of 55
(OR = 1.71; 95 % CI = 0.71–4.11), as well as non-significantly increased all-cause mortality
among those who took secretogogues (HR = 1.90; 95 % CI = 0.54–6.71). We also observed
non-significant decreases in the association between diabetes and breast cancer risk and
mortality among those who took metformin as treatment for their diabetes. We did not
observe any associations for duration of diabetes, receiving treatment, or other treatment
types.
Discussion
This large population-based study suggests a moderate and independently increased risk of
all-cause mortality among women with a breast cancer diagnosis. After adjustment for
menopausal status, race, obesity, and history of MI, breast cancer patients with diabetes had
more than a 60 % increased risk of all-cause mortality than those without diabetes; this
association was more than twofold for women with a BMI of 30 or greater at diagnosis. We
also found that self-reported diabetes was associated with risk of developing breast cancer
among older women and those with a lower BMI as well as those who had gained less
weight during adulthood. In light of the fact that the prevalence of T2D is rapidly increasing,
the results of our study have strong clinical implications for breast cancer prevention and
improving survival.
Our findings of an 65 % increased risk of death due to any cause confirm those found in
population-based studies that also show increased all-cause mortality after breast cancer
diagnosis, finding excess deaths due to diabetes ranging from 35 to 76 % [11, 12, 26, 27].
Although all-cause mortality was significantly increased with diabetes, the association with
mortality due to breast cancer specifically is less clear in our study. Some studies have found
increased associations with breast cancer death [12, 28, 29]; however, other studies have not
found this association [30]. It has been suggested that women with diabetes are less likely to
receive mammography screening [31] and tend to present with more advanced disease at
diagnosis [27]. However, in our study, we saw no difference in mammography use or tumor
stage between women with and without diabetes. It is unclear why the association with all-
cause mortality observed for diabetes is not seen for breast cancer-specific death. Some of
the association could be due in part to medication use reducing insulin and other circulating
hormone levels associated with breast cancer, as nearly three-quarters of diabetics in our
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study regularly took medication for their condition. It is also possible that those with
diabetes are more likely to die of other diseases that share the same risk factors as diabetes
including renal disease, liver disease, and infections [32].
The risk of breast cancer in relation to T2D is thought to be due to increased circulating
levels of insulin that are a direct result of insulin resistance. Biologic mechanisms of how
diabetes can lead to breast cancer and affect prognosis include direct effects of high insulin
levels, which have been shown to promote tumor proliferation, and insulin receptors are
often overexpressed in breast cancer cells [33]. Insulin resistance can also indirectly affect
breast cancer outcomes through increased sex steroid availability through decreases in sex
hormone-binding globulin, increased IGF-I production, and disruption of adipokines [6]. In
addition, T2D has been associated with chronic, low-grade inflammation. It has been shown
that inflammatory molecules produced by adipose tissue as well as macrophages may lead to
insulin resistance [34, 35].
As a result of the different mechanisms involved, medications taken for T2D may affect
breast cancer depending on its mode of action, and there has been a recent effort toward
studying how these medications affect cancer risk. Several studies have shown that
medications that increase insulin levels, including use of insulin or insulin secretogogues,
are associated with increased risk of cancer [16, 17, 36], while it has been suggested that
treatment with insulin sensitizers, including metformin, may reduce risk of developing
breast cancer and recurrence by killing the stem cells that are thought to be responsible for
the spread of breast cancer [37]. We are not aware of any studies that have looked at
medication use and survival after a breast cancer diagnosis; however, there is evidence that
sensitizer medications, specifically metformin, may reduce cancer mortality [38]. While we
were not able to adequately assess diabetes treatment on survival due to sparse data, there
was a suggestion that metformin may reduce mortality and use of secretogogues increased
mortality, although these associations may be biased due to unmeasured factors associated
with medication compliance including regimen complexity, emotional factors, and
medication cost [39]. Our results show no association with breast cancer development for
any type of treatment, which are similar to those of another study, which looked at type of
diabetes treatment and risk of developing breast cancer in women over the age of 65 [40],
and the Nurses’ Health Study that found no increased risk of breast cancer for diabetes
among those taking diabetes medication [22]. A second study of Hispanic women found an
increased risk of developing breast cancer with use of insulin using a control group
consisting of women who had received a diagnostic mammogram due to either inconclusive
or abnormal results [19]. A recent meta-analysis on metformin use also found no association
with breast cancer [41]. Further research is needed to adequately assess the impact of types
of diabetes treatments, including sulfonylureas for which there are no supporting data, on
breast cancer outcomes.
Increased body size is an established risk factor for developing breast cancer in
postmenopausal women and affects survival after breast cancer diagnosis [4, 42]. Increased
body size is also a well-known risk factor for diabetes. Our estimates of association between
diabetes and risk of developing breast cancer did not change with adjustment for obesity.
However, while we found no increased risk of developing breast cancer overall in relation to
diabetes, when we stratified this association by body size, we found an increased risk of
developing breast cancer among women who with a BMI less than 30 (OR = 1.52, 95 % CI
= 1.03–2.25); an association that was even stronger when restricted to those with a BMI<25
(OR = 2.13, 95 % CI = 1.11–4.10). The reasons for these observations are unclear. Perhaps
women with increased body size are at increased risk of postmenopausal breast cancer due
to factors associated with their obesity other than diabetes, such as elevated estrogen levels
[43] and increased adipocytokines [44] that have been shown to increase breast cancer cell
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proliferation and have involvement with angiogenesis. It is possible that women with lower
BMI have fewer risk factors in general, and therefore their diabetes and hyperinsulinemia
would have more of an impact on risk of developing breast cancer. Thus, it is possible that
as is the case for exogenous hormone use, where effects are only evident among women
without an increased body size [45, 46], the risk of breast cancer in association with diabetes
is evident among women without an increased body size. Some researchers have attributed
the interaction between body size and exogenous hormone use as a threshold effect; namely,
the effects of hormone use are not evident among women with increased body size who are
already estrogen-swamped [47]. Clearly, further research is warranted on modulating effects
of body size on the association between diabetes and the risk of developing breast cancer.
We examined the association between diabetes and cancer while controlling for risk factors
that are common to both, including age, obesity, physical activity, dietary factors, and
alcohol consumption. Specifically, we assessed the association of diabetes and breast cancer
with dietary factors often associated with diabetes such as high carbohydrate and high
calorie intake. Our results do not suggest a difference in association when stratified by these
factors. This is not surprising as the associations between these factors and breast cancer
have been mixed [48–50]. However, low physical activity and obesity are strongly linked to
both T2D and breast cancer. Because these factors are interrelated, it makes it difficult to
identify the contribution of each on the relation of diabetes on breast cancer outcomes.
Therefore, we cannot rule out residual confounding as an explanation for our findings.
We found more than a threefold increase in risk of developing breast cancer associated with
diabetes among those of non-white race, although the number of non-white women in the
LIBCSP is low and so cannot rule out chance for these findings. Because of the high
prevalence of diabetes in African American communities, it is widely thought that race and
ethnicity are major contributors to diabetes risk. More recent research, however, has shown
that socioeconomic factors have a stronger association with prevalence of diabetes than race
or ethnicity. Two recent studies report that after considering socioeconomic status, African
Americans [51, 52] and Hispanics [51] have similar risks of diabetes as those found in
Caucasians. In our study, however, after considering menopausal status, obesity, other
comorbidities, income, and education, the association between diabetes and risk of
developing breast cancer remained for non-whites. This may imply that diabetes has a
differential effect on risk of developing breast cancer according to race or may simply imply
that there is an additional unmeasured factor in our study that is driving the relationship.
One reason for this association may be due to waist circumference (WC) that was not
assessed in the LIBCSP. WC, a measure upper body obesity, correlates strongly with
hyperinsulinemia [53] and is greater in African–American women than in white women with
similar BMI [54]. Further research into this association including studies on environmental,
behavioral, and genetic factors is needed.
There are a few limitations of this study that warrant mention. Although diabetes in our
study was self-reported and did not distinguish between type 1 and type 2 diabetes, the
majority of women who reported taking diabetes medications listed medications that are
used to treat type 2 diabetes (85 %). Additionally, it is estimated that only 2.7 % of the
population ages 20–44 has either undiagnosed or diagnosed diabetes [55]. Of the women in
our study who reported having diabetes, 18 (7.8 %) women had a diabetes diagnosis before
the age of 30, only 4 of whom were diagnosed before the age of 20. We excluded from
analyses all women who reported having been diagnosed with diabetes before age 30 to
increase the probability that the diabetes under investigation was adult-onset. However, we
were not able to assess laboratory measurements that would confirm a diabetes diagnosis,
nor were we able to adequately assess certain aspects of diabetes in relation to risk of
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developing breast cancer, such as types and duration of therapies due to the low numbers of
participants with diabetes reporting use of specific types of therapies.
Our findings show that diabetes increases breast cancer risk and mortality in older women,
regardless of hormone receptor status of the tumor. This has strong clinical implications as
the prevalence of diabetes in the United States continues to increase, which could result in a
large number of women who could be at risk of excess death after a breast cancer diagnosis.
Identification of factors that affect breast cancer risk and survival could help health care
providers better counsel to their patients by offering screening for diabetes as well as
developing interventions aimed at preventing T2D and better maintenance of diabetes,
including coordination of diabetes and breast cancer treatments.
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Table 1
Selected characteristics of women diagnosed with a first primary breast cancer in 1996–1997, Long Island
Breast Cancer Study Project, by diabetes status prior to diagnosis
Characteristics Diabetes No diabetes p Value
Mean age (years) 63.6 57.4 <0.0001
Breast cancer diagnosis (%) 55.7 48.7 0.046
5-year death due to breast cancer (%among cases) 11.5 6.7 0.049
Menopausal status (%postmenopausal) 86.2 65.6 <0.0001
Race (% Caucasian) 84.9 93.4 <0.0001
BMI, mean 30.9 26.1 <0.0001
Energy intake (Kcal/day), mean 1,316 1,343 0.594
Regular physical activity (≥3 h/week) (%) 61.9 71.8 0.002
Ever regular alcohol drinker (%) 42.9 64.0 <0.0001
Ever take hormone replacement (%) 20.4 33.5 0.0003
Breast cancer stage (% invasive among cases) 87.7 84.1 0.287
ER + tumor (% among cases) 73.6 73.6 0.997
PR + tumor (% among cases) 66.7 64.0 0.619
Chemotherapy (% among cases) 33.9 41.9 0.239
Hormone therapy (% among cases) 72.2 60.6 0.089
Radiation therapy (% among cases) 50.0 61.7 0.081
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